Upgrade to SI Premium - Free Trial

Truist Securities Reiterates Buy Rating on Abbvie (ABBV) Despite Humira Erosion, With Focus on Skyrizi/Rinvoq

July 29, 2022 3:31 PM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $160.00 price target on Abbvie (NYSE: ABBV) following results, which ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View